Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | IONS |
---|---|---|
09:32 ET | 10799 | 40.36 |
09:34 ET | 1924 | 40.36 |
09:36 ET | 300 | 40.145 |
09:38 ET | 100 | 40.08 |
09:41 ET | 350 | 40.08 |
09:43 ET | 515 | 40.01 |
09:45 ET | 10214 | 40.095 |
09:48 ET | 2563 | 40.055 |
09:50 ET | 1826 | 40.11 |
09:52 ET | 1082 | 40.11 |
09:54 ET | 26134 | 40.14 |
09:56 ET | 8467 | 40.22 |
09:57 ET | 500 | 40.3 |
09:59 ET | 1600 | 40.3 |
10:01 ET | 2000 | 40.29 |
10:03 ET | 600 | 40.355 |
10:06 ET | 100 | 40.335 |
10:08 ET | 956 | 40.35 |
10:10 ET | 3173 | 40.31 |
10:12 ET | 1844 | 40.24 |
10:14 ET | 4550 | 40.205 |
10:15 ET | 12207 | 40.28 |
10:17 ET | 8725 | 40.24 |
10:19 ET | 4558 | 40.25 |
10:21 ET | 2167 | 40.24 |
10:26 ET | 1400 | 40.21 |
10:28 ET | 2293 | 40.2 |
10:30 ET | 40131 | 40.29 |
10:32 ET | 950 | 40.31 |
10:33 ET | 229 | 40.32 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Ionis Pharmaceuticals Inc | 5.8B | -15.1x | --- |
Halozyme Therapeutics Inc | 6.5B | 20.8x | --- |
Apellis Pharmaceuticals Inc | 5.1B | -12.4x | --- |
CRISPR Therapeutics AG | 5.1B | -24.2x | --- |
Guardant Health Inc | 3.7B | -7.9x | --- |
Intra-Cellular Therapies Inc | 7.3B | -60.0x | --- |
Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.8B |
---|---|
Revenue (TTM) | $776.6M |
Shares Outstanding | 146.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.36 |
EPS | $-2.67 |
Book Value | $2.68 |
P/E Ratio | -15.1x |
Price/Sales (TTM) | 7.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -48.38% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.